MedTrace Logo

Ropivacaine Transversus Abdominis Plane Blocks for Cesarean Section Analgesia

NCT02893423 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2022-09-21

Study results available
· View outcomes & findings →

Summary

With this research the investigators hope to determine the lowest dose of ropivacaine used in transversus abdominis plane (TAP) blocks that can effectively treat pain in women after cesarean section (c-section).

Conditions

  • Postoperative Pain

Interventions

DRUG

Ropivacaine

Using 2 Different Concentrations of Ropivacaine in Tap Block for Postoperative Analgesia for C-Section Patients

Sponsors & Collaborators

  • Maimonides Medical Center

    lead OTHER

Principal Investigators

  • KALPANA TYAGARAJ, MD · MAIMONIDES MEDICAL CENTER, 4802, 10TH AVENUE, BROOKLYN, NY-11219

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-01-01
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02893423 on ClinicalTrials.gov